These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38630027)

  • 1. Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma.
    Lee HW; Kim SM; Park HD
    Clin Chem Lab Med; 2024 Oct; 62(11):2223-2232. PubMed ID: 38630027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay.
    Thoren KL; Pianko MJ; Maakaroun Y; Landgren CO; Ramanathan LV
    J Appl Lab Med; 2019 Mar; 3(5):857-863. PubMed ID: 31639760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma.
    Thoren K; Menad S; Nouadje G; Macé S
    J Appl Lab Med; 2024 Jul; 9(4):661-671. PubMed ID: 38573925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitigating the interference of Daratumumab with immunofixation electrophoresis. A single-center experience using Hydrashift 2/4 kit.
    Duek A; Lellouche E; Ben Baruch S; Mashiach R; Segman Y; Bryk G; Leiba M
    Isr Med Assoc J; 2022 Oct; 24(10):629-633. PubMed ID: 36309856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application of Hydrashift 2/4 daratumumab assay in eliminating interference of daratumumab on serum immunofixation electrophoresis].
    Xu S; Liu Y; Wen L; Zhao L; Deng X; Rong R; Lu J
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):840-845. PubMed ID: 34788924
    [No Abstract]   [Full Text] [Related]  

  • 6. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
    Noori S; Verkleij CPM; Zajec M; Langerhorst P; Bosman PWC; de Rijke YB; Zweegman S; VanDuijn M; Luider T; van de Donk NWCJ; Jacobs JFM
    Clin Chem Lab Med; 2021 Nov; 59(12):1963-1971. PubMed ID: 34392637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of M-protein detection on the response evaluations of patients undergoing treatment with the IgG-κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis (IFE) systems and reagents.
    Shirouchi Y; Kaihara K; Sekita T; Amano N; Nakayama K; Miyake K; Abe H; Oinuma H; Maruyama D
    Cancer Med; 2024 Aug; 13(16):e70128. PubMed ID: 39177082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a Daratumumab-Specific Immunofixation Assay to Assess Possible Immunotherapy Interference at a Major Cancer Center: Our Experience and Recommendations.
    Kirchhoff DC; Murata K; Thoren KL
    J Appl Lab Med; 2021 Nov; 6(6):1476-1483. PubMed ID: 34293131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab.
    Jimenez A; Scholl AR; Wang B; Schilke M; Carlsen ED
    Clin Biochem; 2024 May; 127-128():110761. PubMed ID: 38565341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
    van de Donk NW; Otten HG; El Haddad O; Axel A; Sasser AK; Croockewit S; Jacobs JF
    Clin Chem Lab Med; 2016 Jun; 54(6):1105-9. PubMed ID: 26812873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
    McCudden C; Axel AE; Slaets D; Dejoie T; Clemens PL; Frans S; Bald J; Plesner T; Jacobs JF; van de Donk NW; Moreau P; Schecter JM; Ahmadi T; Sasser AK
    Clin Chem Lab Med; 2016 Jun; 54(6):1095-104. PubMed ID: 27028734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.
    Moore LM; Cho S; Thoren KL
    Clin Chim Acta; 2019 May; 492():91-94. PubMed ID: 30790545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells.
    Wang H; Koob T; Fromm JR; Gopal A; Carter D; Lieber A
    Cancer Biol Ther; 2024 Dec; 25(1):2314322. PubMed ID: 38361357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring.
    Liu L; Wertz WJ; Kondisko A; Shurin MR; Wheeler SE
    J Appl Lab Med; 2020 Jan; 5(1):29-40. PubMed ID: 32445341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
    Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
    Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
    [No Abstract]   [Full Text] [Related]  

  • 16. Electrophoretic patterns post daratumumab.
    Sheldon J; Wheeler RD; Powles R
    Ann Clin Biochem; 2018 Mar; 55(2):299-301. PubMed ID: 28490184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative assessment of daratumumab in serum
    Canil G; Miolo G; Simula M; Rupolo M; Steffan A; Corona G
    Anal Methods; 2024 Jul; 16(26):4240-4246. PubMed ID: 38780038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
    Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
    Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping.
    Chami B; Okuda M; Moayeri M; Pirenne F; Hidaka Y; Nambiar A; Song Z; Bedel O; Zhang B; Hopke J; Deng G; Zhu C; Macé S; Chiron M; Adrian F; Fukao T; Basile FG; Martin T
    Transfusion; 2022 Nov; 62(11):2334-2348. PubMed ID: 36239134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
    Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ
    Lancet Haematol; 2020 May; 7(5):e370-e380. PubMed ID: 32213342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.